Alvocidib companion diagnostic - Eutropics/Tolero Pharmaceuticals

Drug Profile

Alvocidib companion diagnostic - Eutropics/Tolero Pharmaceuticals

Alternative Names: Praedicare DxTM

Latest Information Update: 31 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eutropics Pharmaceuticals
  • Developer Eutropics Pharmaceuticals; Tolero Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 26 Jan 2017 Tolero Pharmaceuticals has been acquired by Sumitomo Dainippon Pharma
  • 28 Dec 2016 Preclinical trials in Myelodysplastic syndromes (Diagnosis) in USA (unspecified route)
  • 09 Nov 2015 PraediCare Dx™ platform licensed to Tolero Pharmaceuticals for alvocidib
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top